ストックスクリーナーアプリを入手
4.10
2.50%
0.10
アフターアワーズ：
4.10
前日終値:
$4.00
開ける：
$4.11
24時間の取引高:
717
Relative Volume:
0.12
時価総額：
$165.54M
収益：
$7.80M
当期純損益:
$-69.02M
株価収益率:
-1.9147
EPS:
-2.1413
ネットキャッシュフロー:
$-66.61M
1週間 パフォーマンス:
-2.15%
1か月 パフォーマンス:
+15.82%
6か月 パフォーマンス:
+1.49%
1年 パフォーマンス:
-27.37%
1日の値動き範囲:
$4.10
$4.11
1週間の範囲:
$3.99
$4.2273
52週間の値動き範囲:
$3.36
$5.99
Molecular Partners Ag Adr Stock (MOLN) Company Profile
MOLN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MOLN
Molecular Partners Ag Adr
|
4.10 | 149.60M | 7.80M | -69.02M | -66.61M | -2.1413 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.17 | 109.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.61 | 82.75B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
445.12 | 56.78B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
917.63 | 56.52B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.51 | 44.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Molecular Partners Ag Adr Stock (MOLN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-08-30 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-08-29 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2022-05-25 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2022-04-27 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2021-07-13 | 開始されました | Cowen | Outperform |
| 2021-07-12 | 再開されました | SVB Leerink | Outperform |
すべてを表示
Molecular Partners Ag Adr (MOLN) 最新ニュース
Molecular Partners Reports Q3 2025 Financial Results and Clinical Progress, with DLL3-Targeting Radio-DARPin MP0712 Phase 1 Launch Expected in 2025 - GlobeNewswire Inc.
Molecular Partners (NASDAQ:MOLN) Stock Price Down 2.1% – Here’s What Happened - Defense World
Molecular Partners AG (MOLNZ.XC) Stock Price, News, Quote & History - Yahoo
Molecular Partners (NASDAQ:MOLN) Trading 1.5% HigherHere's What Happened - MarketBeat
Liminatus Pharma (LIMN) Short Interest Ratio and Volume 2025 - MarketBeat
Molecular Partners (NASDAQ:MOLN) Price Target Cut to $4.00 by Analysts at JPMorgan Chase & Co. - MarketBeat
Leerink Partnrs Has Bullish Estimate for MOLN Q3 Earnings - MarketBeat
Leerink Partnrs Issues Positive Outlook for MOLN Earnings - Defense World
EHang, Molecular Partners And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Why Serina Therapeutics Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket - Benzinga
Molecular Partners Ag shares rise 3.64% intraday after Voyager Therapeutics expands Alzheimer's disease franchise. - AInvest
Molecular Partners (NASDAQ:MOLN) Stock Price Down 3.4% – Should You Sell? - Defense World
Molecular Partners and Orano Med Present Promising Preclinical Data on MP0726, a Radio-DARPin Candidate for Ovarian Cancer Treatment - AInvest
Molecular Partners shares rise 1.93% after-hours after presenting positive data from ongoing Phase 1/2A trial. - AInvest
Molecular Partners Cuts 40 Jobs, Extends Cash Reach to 2028 - AInvest
Molecular Partners Ag shares rise 6.71% intraday after MIT and Recursion release Boltz-2 AI model. - AInvest
US NYSE/NASD Stock Directory - Minichart
Walmart, Deere, Applied Materials set to report earnings Thursday - Investing.com
Molecular Partners' AACR 2025 Breakthroughs: Radio-DARPins and Smart T Cell Engagers Ignite Oncology Potential - AInvest
J.P. Morgan Keeps Their Buy Rating on Novo Nordisk (0QIU) - The Globe and Mail
TD Cowen maintains Buy on Molecular Partners, target CHF15 - Investing.com
Molecular Partners (MOLN) Stock Trends and Sentiment 2025 - MarketBeat
Molecular Partners (MOLN) Stock Forecast and Price Target 2025 - MarketBeat
Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting By Investing.com - Investing.com South Africa
symbol__ Stock Quote Price and Forecast - CNN
Molecular Partners: Sellers Have Disappeared, Enterprise Value Below Zero (NASDAQ:MOLN) - Seeking Alpha
What is the current Price Target and Forecast for Molecular Partners AG Sponsored ADR (MOLN) - Zacks Investment Research
US stock market gainers for the last week of April 2022 - Nairametrics
Novartis and Molecular Partners report positive topline data from Phase 2 study for ensovibep (MP0420), a DARPin antiviral therapeutic for COVID-19 - Novartis
Molecular Partners (MOLN) 10K Form and SEC Filings 2025 - MarketBeat
Evaxion A/S (EVAX) Short Interest & Short Float | Updated Nov 2025 - MarketBeat
Citi Appointed as Depositary Bank for Molecular Partners AG’s ADR Programme - Business Wire
Molecular Partners AG Sponsored ADR (MOLN) - Zacks Investment Research
Molecular Partners (MOLN) Earnings Date and Reports 2025 - MarketBeat
Molecular Partners (MOLN) Competitors and Alternatives 2025 - MarketBeat
Molecular Partners (MOLN) Stock Price, News & Analysis - MarketBeat
MOLN Stock Price and Chart — NASDAQ:MOLN - TradingView
Novartis and Molecular Partners announce start of EMPATHY clinical trial for ensovibep for the treatment of COVID-19 - Novartis
Valneva SE (VALN) Stock Price, News, Quote & History - Yahoo
Novartis announces collaboration with Molecular Partners to develop two DARPin® therapies designed for potential use against COVID-19 - Novartis
Applied Therapeutics (APLT) Short Interest & Short Float | Updated Nov 2025 - MarketBeat
PDS Biotechnology (PDSB) Short Interest Ratio and Volume 2025 - MarketBeat
MLLCF News Today | Why did Molecular Partners stock go up today? - MarketBeat
Conference Calls and Individual Investors - MarketBeat
RocheDoing now what patients need next - Roche
MOLN Stock Price and Chart — SIX:MOLN - TradingView
Molecular Partners Ag Adr (MOLN) 財務データ
収益
当期純利益
現金流量
EPS
0.76%
2.16%
大文字化:
|
ボリューム (24 時間):